Vanda Pharmaceuticals Inc. (VNDA)Healthcare | Biotechnology | Washington, United States | NasdaqGM
5.29 USD
-0.15
(-2.757%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 5.29 |
Hot Take ↕ | Aug. 22, 2026, 4:06 a.m. EDT
The long-term outlook is severely compromised by a brutal four-year streak of declining annual returns, which has dragged the stock down nearly 62% from its peak. Despite the company's strong gross margins and a recent FDA acceptance for a new filing, the market has priced in significant structural deterioration, evidenced by shrinking revenue and negative operating cash flow. The balance sheet is fragile, with free cash burn exceeding $86 million annually and minimal liquidity relative to debt obligations. While the short-term chart shows some stabilization near the $5 level, the lack of a dividend and the overwhelming weight of negative historical performance suggest this is a speculative turnaround play rather than a sound investment. The options market confirms this skepticism, with traders loading up on downside protection. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.108718 |
| AutoETS | 0.108755 |
| MSTL | 0.114411 |
| AutoTheta | 0.120211 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 6.79 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.171 |
| Excess Kurtosis | -0.98 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.369 |
| Revenue per Share | 3.627 |
| Market Cap | 319,847,616 |
| Forward P/E | 26.45 |
| Beta | 0.64 |
| Profit Margins | -127.41% |
| Website | https://www.vandapharma.com |
As of Aug. 22, 2026, 4:06 a.m. EDT: Speculators are positioning defensively with heavy open interest in out-of-the-money puts (706 contracts at the $5 strike for September expiration), indicating a fear of further downside. Call activity is sparse and concentrated near the money, while implied volatility remains elevated, suggesting uncertainty rather than a clear bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.15498936 |
| Address1 | 2,200 Pennsylvania Avenue NW |
| Address2 | Suite 300E |
| All Time High | 33.44 |
| All Time Low | 0.45 |
| Ask | 5.78 |
| Ask Size | 1 |
| Audit Risk | 3 |
| Average Daily Volume10 Day | 835,110 |
| Average Daily Volume3 Month | 931,659 |
| Average Volume | 931,659 |
| Average Volume10Days | 835,110 |
| Beta | 0.638 |
| Bid | 4.37 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 4.669 |
| City | Washington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.29 |
| Current Ratio | 1.612 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.435 |
| Day Low | 5.2201 |
| Debt To Equity | 10.369 |
| Display Name | Vanda Pharmaceuticals |
| Earnings Call Timestamp End | 1,785,961,800 |
| Earnings Call Timestamp Start | 1,785,961,800 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -177,047,008 |
| Ebitda Margins | -0.82071996 |
| Enterprise To Ebitda | -0.975 |
| Enterprise To Revenue | 0.8 |
| Enterprise Value | 172,650,608 |
| Eps Forward | 0.2 |
| Eps Trailing Twelve Months | -4.51 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.569 |
| Fifty Day Average Change | -0.2789998 |
| Fifty Day Average Change Percent | -0.05009873 |
| Fifty Two Week Change Percent | 15.498936 |
| Fifty Two Week High | 9.94 |
| Fifty Two Week High Change | -4.6499996 |
| Fifty Two Week High Change Percent | -0.46780682 |
| Fifty Two Week Low | 4.27 |
| Fifty Two Week Low Change | 1.02 |
| Fifty Two Week Low Change Percent | 0.23887588 |
| Fifty Two Week Range | 4.27 - 9.94 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,144,848,600,000 |
| Float Shares | 47,660,318 |
| Forward Eps | 0.2 |
| Forward P E | 26.449999 |
| Free Cashflow | -86,717,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 533 |
| Fullday Change | -0.15 |
| Fullday Change Percent | -2.75735 |
| Fullday Price | 5.29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.93738997 |
| Gross Profits | 202,215,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06612 |
| Held Percent Institutions | 0.86411005 |
| Implied Shares Outstanding | 60,462,687 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia. |
| Long Name | Vanda Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 319,847,616 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_24545059 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -274,852,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 328,917,017 |
| Number Of Analyst Opinions | 4 |
| Open | 5.4 |
| Operating Cashflow | -142,331,008 |
| Operating Margins | -1.26282 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.23 |
| Phone | 202 734 3400 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 5.29 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 5.44 |
| Price Hint | 2 |
| Price To Book | 1.1330049 |
| Price To Sales Trailing12 Months | 1.4826912 |
| Profit Margins | -1.2741101 |
| Quick Ratio | 1.401 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.15 |
| Regular Market Change Percent | -2.75735 |
| Regular Market Day High | 5.435 |
| Regular Market Day Low | 5.2201 |
| Regular Market Day Range | 5.2201 - 5.435 |
| Regular Market Open | 5.4 |
| Regular Market Previous Close | 5.44 |
| Regular Market Price | 5.29 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 525,249 |
| Return On Assets | -0.22376 |
| Return On Equity | -0.77805 |
| Revenue Growth | -0.039 |
| Revenue Per Share | 3.627 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 60,462,687 |
| Shares Percent Shares Out | 0.1268 |
| Shares Short | 7,668,642 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 7,188,123 |
| Short Name | Vanda Pharmaceuticals Inc. |
| Short Percent Of Float | 0.1331 |
| Short Ratio | 7.56 |
| Source Interval | 15 |
| State | DC |
| Symbol | VNDA |
| Target High Price | 20.0 |
| Target Low Price | 5.75 |
| Target Mean Price | 12.1875 |
| Target Median Price | 11.5 |
| Total Cash | 170,028,992 |
| Total Cash Per Share | 2.812 |
| Total Debt | 22,832,000 |
| Total Revenue | 215,720,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.51 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.54545 |
| Two Hundred Day Average Change | -1.2554502 |
| Two Hundred Day Average Change Percent | -0.19180502 |
| Type Disp | Equity |
| Volume | 525,249 |
| Website | https://www.vandapharma.com |
| Zip | 20,037 |